13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001482416
Total reported value
$604.3M
$604.3M
39 檔
19.9%
In Q3 2024, Sio Capital Management, LLC's U.S. equity holdings reached a combined market value of $604.3M, distributed across 39 disclosed stock positions.
In Q3 2024, Sio Capital Management, LLC adopted a defensive or profit-taking posture, trimming 13 positions and completely liquidating 18 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | LH | Labcorp Holdings Inc | Stock-Healthcare | 15.36% | — | -29.53% | |
| 2 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 11.49% | — | — | |
| 3 | TEVA | Teva Pharmaceutical-sp Adr | Stock-Healthcare | 9.64% | — | — | |
| 4 | MMS | Maximus Inc | Stock-Industrials | 5.73% | -0.71% | — | |
| 5 | ZBH | Zimmer Biomet Holdings Inc | Stock-Healthcare | 5.46% | +1.06% | -17.90% | |
| 6 | VXRT | Vaxart Inc | Stock-Other | 4.58% | — | -7.83% | |
| 7 | KVUE | Kenvue Inc | Stock-Consumer Staples | 4.35% | — | -2.12% | |
| 8 | TFX | Teleflex Inc | Stock-Healthcare | 3.85% | -1.63% | EXIT | |
| 9 | TYRA | Tyra Biosciences Inc | Stock-Other | 3.74% | +0.35% | -33.22% | |
| 10 | IRON | Disc Medicine Inc | Stock-Other | 3.66% | -0.60% | EXIT | |
| 11 | CI | THE Cigna Group | Stock-Healthcare | 3.64% | +2.63% | NEW | |
| 12 | ANNX | Annexon Inc | Stock-Other | 3.36% | — | — | |
| 13 | ✓ | Biodesix Inc | Stock-Other | 3.06% | — | -0.21% | |
| 14 | RLAY | Relay Therapeutics Inc | Stock-Other | 2.66% | — | — | |
| 15 | ERAS | Erasca Inc | Stock-Other | 2.40% | -0.01% | EXIT | |
| 16 | CMPS | Compass Pathways PLC | Stock-Other | 2.28% | -1.19% | EXIT | |
| 17 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 2.20% | — | -1.05% | |
| 18 | PMVP | Pmv Pharmaceuticals Inc | Stock-Other | 1.90% | +0.03% | +18.68% | |
| 19 | VTYXUSD | Ventyx Biosciences Inc | Stock-Other | 1.70% | — | +153.16% | |
| 20 | IDYA | Ideaya Biosciences Inc | Stock-Other | 1.55% | +2.96% | NEW | |
| 21 | AORT | Artivion Inc | Stock-Other | 1.28% | +0.18% | NEW | |
| 22 | CRGX | Cargo Therapeutics Inc | Stock-Other | 1.27% | — | — | |
| 23 | CNTX | Context Therapeutics Inc | Stock-Other | 1.03% | -0.34% | EXIT | |
| 24 | ENTA | Enanta Pharmaceuticals Inc | Stock-Other | 0.73% | -0.07% | EXIT | |
| 25 | NUVB | Nuvation Bio Inc | Stock-Other | 0.61% | — | — | |
| 26 | FHTX | Foghorn Therapeutics Inc | Stock-Other | 0.45% | -0.08% | EXIT | |
| 27 | ASNSUSD | X4 Pharmaceuticals Inc | Stock-Other | 0.35% | — | -47.86% | |
| 28 | APRE | Aprea Therapeutics Inc | Stock-Other | 0.30% | — | — | |
| 29 | AVTX | Avalo Therapeutics Inc | Stock-Other | 0.27% | — | — | |
| 30 | ✓ | Rapt Therapeutics Inc | Stock-Other | 0.25% | — | — | |
| 31 | BOLD | Boundless Bio Inc | Stock-Other | 0.22% | -0.03% | EXIT | |
| 32 | ✓ | Nyxoah S A | Stock-Other | 0.19% | -0.02% | EXIT | |
| 33 | VSTM | Verastem Inc | Stock-Other | 0.16% | — | — | |
| 34 | ✓ | Modular Med Inc | Stock-Other | 0.11% | — | -92.15% | |
| 35 | NXTCEUR | Nextcure Inc | Stock-Other | 0.07% | — | — | |
| 36 | HUMAW | Humacyte Inc-cw27 | Stock-Other | 0.04% | — | — | |
| 37 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 0.03% | -0.08% | EXIT | |
| 38 | RCKTW | Rocket Pharmaceuticals In-27 | Stock-Other | 0.01% | — | — | |
| 39 | ✓ | Stock-Other | — | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ISRG | Intuitive Surgical Inc | +11.5% | NEW | New buy |
| 2 | TEVA | Teva Pharmaceutical-sp Adr | +9.6% | NEW | New buy |
| 3 | MMS | Maximus Inc | +5.7% | NEW | New buy |
| 4 | ANNX | Annexon Inc | +3.4% | NEW | New buy |
| 5 | RLAY | Relay Therapeutics Inc | +2.7% | NEW | New buy |
| 6 | KVUE | Kenvue Inc | +2% | -2.12% | Trim |
| 7 | VXRT | Vaxart Inc | +1.9% | -7.83% | Trim |
| 8 | LH | Labcorp Holdings Inc | +1.8% | -29.53% | Trim |
| 9 | CMPS | Compass Pathways PLC | +1.8% | +211.72% | Add |
| 10 | IDYA | Ideaya Biosciences Inc | +1.6% | NEW | New buy |
| 11 | IRON | Disc Medicine Inc | +1.3% | -2.11% | Trim |
| 12 | AORT | Artivion Inc | +1.3% | NEW | New buy |
| 13 | CRGX | Cargo Therapeutics Inc | +1.3% | NEW | New buy |
| 14 | ✓ | Biodesix Inc | +1.3% | -0.21% | Trim |
| 15 | CI | THE Cigna Group | +1.2% | -1.06% | Trim |
| 16 | VTYXUSD | Ventyx Biosciences Inc | +1.2% | +153.16% | Add |
| 17 | TYRA | Tyra Biosciences Inc | +1.1% | -33.22% | Trim |
| 18 | CATBUSD | Astria Therapeutics Inc | +0.9% | -1.05% | Trim |
| 19 | ZBH | Zimmer Biomet Holdings Inc | +0.9% | -17.90% | Trim |
| 20 | PMVP | Pmv Pharmaceuticals Inc | +0.7% | +18.68% | Add |
| 21 | ERAS | Erasca Inc | +0.6% | -22.80% | Trim |
| 22 | CNTX | Context Therapeutics Inc | +0.3% | — | Unchanged |
| 23 | FHTX | Foghorn Therapeutics Inc | +0.3% | — | Unchanged |
| 24 | ENTA | Enanta Pharmaceuticals Inc | +0.1% | — | Unchanged |
| 25 | ✓ | Nyxoah S A | +0.1% | — | Unchanged |
| 26 | NUVB | Nuvation Bio Inc | +0.1% | — | Unchanged |
| 27 | BOLD | Boundless Bio Inc | +0.1% | — | Unchanged |
| 28 | VSTM | Verastem Inc | +0.1% | — | Unchanged |
| 29 | AVTX | Avalo Therapeutics Inc | 0% | — | Unchanged |
| 30 | 430 | Terns Pharmaceuticals Inc | 0% | NEW | New buy |
| 31 | HUMAW | Humacyte Inc-cw27 | 0% | — | Unchanged |
| 32 | NXTCEUR | Nextcure Inc | 0% | — | Unchanged |
| 33 | APRE | Aprea Therapeutics Inc | — | — | Unchanged |
| 34 | ✓ | — | — | Unchanged | |
| 35 | RCKTW | Rocket Pharmaceuticals In-27 | — | — | Unchanged |
| 36 | ✓ | Rapt Therapeutics Inc | 0% | — | Unchanged |
| 37 | ✓ | Aslan Pharmaceuticals LTD | 0% | EXIT | Sold out |
| 38 | ASNSUSD | X4 Pharmaceuticals Inc | 0% | -47.86% | Trim |
| 39 | PRLD | Prelude Therapeutics Inc | -0.3% | EXIT | Sold out |
| 40 | ARQT | Arcutis Biotherapeutics Inc | -0.4% | EXIT | Sold out |
| 41 | SPRY | Ars Pharmaceuticals Inc | -0.5% | EXIT | Sold out |
| 42 | ✓ | Modular Med Inc | -0.6% | -92.15% | Trim |
| 43 | ✓ | Third Harmonic Bio Inc | -0.6% | EXIT | Sold out |
| 44 | STOK | Stoke Therapeutics Inc | -0.6% | EXIT | Sold out |
| 45 | APGE | Apogee Therapeutics Inc | -0.8% | EXIT | Sold out |
| 46 | BBIO | Bridgebio Pharma Inc | -0.9% | EXIT | Sold out |
| 47 | ZYME | Zymeworks Inc | -1.1% | EXIT | Sold out |
| 48 | BLCO | Bausch + Lomb CORP | -1.2% | EXIT | Sold out |
| 49 | ANIP | Ani Pharmaceuticals Inc | -1.2% | EXIT | Sold out |
| 50 | TFX | Teleflex Inc | -2.5% | -64.64% | Trim |
According to official SEC Form 13F filings, Sio Capital Management, LLC reported a total U.S. public equity portfolio value of $604.3M across 39 disclosed positions in Q3 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including LH, ISRG, TEVA) accounted for 19.9% of total reported equity market value during Q3 2024.
Top New Position Initiated
ISRG
市值: $29.0M
Top Position Liquidated / Trimmed
INSM
前期市值: $91.3M
During Q3 2024, Sio Capital Management, LLC's top holdings by market value included LH (15.4%)、ISRG (11.5%)、TEVA (9.6%). The largest single position, LH, represented 15.4% of total portfolio value.
In Q3 2024, Sio Capital Management, LLC made 43 total portfolio adjustments, initiating 9 new buys, adding to 3 positions, trimming 13 holdings, and fully liquidating 18 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.